Breast Cancer

Taxotere-based regimens with Herceptin in early-stage HER2 breast cancer raise survival rate

Published in Physician Law Weekly, January 17th, 2007

The Cancer International Research Group (CIRG) and sanofi-aventis Group announced the results from the second interim efficacy and safety analysis from the BCIRG 006 phase 3 breast cancer study, which confirms, at a 3-year median follow-up, that Herceptin combined with Taxotere-based regimens significantly improved disease-free survival for women with early HER2-positive breast cancer.

The BCIRG 006 study randomized patients to receive the control arm AC-T, which comprised 4 cycles of doxorubicin (A) and cyclophosphamide (C) followed by 4 cycles of Taxotere (T), or either of two experimental Herceptin (H)- and Taxotere-based therapies: AC-TH (adds 1 year of Herceptin to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2007-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry